Publications by authors named "B Mora"
Article Synopsis
- The study presents a new way to detect pancreatic cancer early using biofluid spectroscopy combined with a specialized machine learning approach.
- By applying distinct techniques like PCA, LDA, and SVM on both cancerous and non-cancerous samples, the researchers achieved better diagnostic accuracy than traditional methods.
- Their findings indicate that this innovative method could lead to effective, non-invasive diagnostic tools for identifying early-stage pancreatic cancer.
Article Synopsis
- - The introduction of small molecule tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) has significantly improved patient life expectancy, making it comparable to the general population, despite potential mild to severe side effects from long-term use.
- - Emerging goals in CML treatment include the potential for treatment-free remission (TFR), with specific eligibility criteria, where 25%-30% of patients might achieve prolonged TFR.
- - This review focuses on guidelines for safely stopping TKIs, shares clinical insights from trials and real-world data, and highlights ongoing research into biological markers that could help predict TFR success.
Purpose Of Review: Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). Median overall survival (OS) of pre-PMF, overt-PMF and SMF patients is around 14 years, seven and nine years, respectively. Main causes of mortality are non-clonal progression and transformation into blast phase.
View Article and Find Full Text PDFArticle Synopsis
- JAK2V617F is the most common genetic mutation in Philadelphia-negative chronic Myeloproliferative Neoplasms (MPNs), and researchers believe abnormalities in Chromosome 9 may influence the disease in patients with this mutation.
- A specific group of MPN patients, called +9p patients, were found to have three copies of the JAK2 gene and nearby genes, leading to increased production of the immunosuppressive PD-L1 protein.
- The study showed that these +9p patients have a distinct cancer profile, characterized by greater stem cell-like properties and an immune response that results in exhausted T cells, highlighting a complex interaction between +9p and JAK2V617F mutations.
Article Synopsis
- - A new framework for defining anemia severity and treatment response in myelofibrosis (MF) aims to improve clinical studies and comparisons as new drugs emerge in this area.
- - The revised criteria will address gender differences in hemoglobin levels and update the definition of transfusion-dependent anemia (TDA) to align with current practices.
- - The updated guidelines introduce specific eligibility thresholds for hemoglobin levels and establish distinct response criteria (major vs. minor) while maintaining a 12-week observation period on treatment.